ALNY Alnylam Pharmaceuticals Inc

Price (delayed)

$151.09

Market cap

$19.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.52

Enterprise value

$19.52B

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is ...

Highlights
The company's revenue has surged by 76% YoY and by 6% QoQ
The gross profit has soared by 75% YoY and by 4.8% from the previous quarter
The equity has contracted by 39% YoY and by 33% from the previous quarter
The company's quick ratio fell by 9% YoY

Key stats

What are the main financial stats of ALNY
Market
Shares outstanding
125.95M
Market cap
$19.03B
Enterprise value
$19.52B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
10.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.68
Earnings
Revenue
$1.83B
EBIT
-$312.3M
EBITDA
-$215.27M
Free cash flow
$41.95M
Per share
EPS
-$3.52
Free cash flow per share
$0.34
Book value per share
-$1.76
Revenue per share
$14.64
TBVPS
$30.66
Balance sheet
Total assets
$3.83B
Total liabilities
$4.05B
Debt
$1.31B
Equity
-$220.64M
Working capital
$2.01B
Liquidity
Debt to equity
-5.92
Current ratio
3.08
Quick ratio
2.86
Net debt/EBITDA
-2.29
Margins
EBITDA margin
-11.8%
Gross margin
83%
Net margin
-24.1%
Operating margin
-15.4%
Efficiency
Return on assets
-12.2%
Return on equity
N/A
Return on invested capital
-9.5%
Return on capital employed
-10.9%
Return on sales
-17.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALNY stock price

How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
-2.67%
1 week
-7.2%
1 month
-16.51%
1 year
-21.08%
YTD
-21.06%
QTD
-21.06%

Financial performance

How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$1.83B
Gross profit
$1.52B
Operating income
-$282.18M
Net income
-$440.24M
Gross margin
83%
Net margin
-24.1%
The company's operating margin has surged by 80% YoY and by 25% QoQ
The net margin has soared by 78% YoY and by 19% from the previous quarter
The company's revenue has surged by 76% YoY and by 6% QoQ
The gross profit has soared by 75% YoY and by 4.8% from the previous quarter

Growth

What is Alnylam Pharmaceuticals's growth rate over time

Valuation

What is Alnylam Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
10.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.68
ALNY's EPS has surged by 62% year-on-year and by 14% since the previous quarter
The equity has contracted by 39% YoY and by 33% from the previous quarter
The company's revenue has surged by 76% YoY and by 6% QoQ
ALNY's price to sales (P/S) is 72% lower than its 5-year quarterly average of 37.0 and 38% lower than its last 4 quarters average of 16.7

Efficiency

How efficient is Alnylam Pharmaceuticals business performance
ALNY's return on sales has surged by 82% year-on-year and by 23% since the previous quarter
ALNY's return on invested capital has surged by 69% year-on-year and by 19% since the previous quarter
The return on assets has surged by 63% year-on-year and by 15% since the previous quarter

Dividends

What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALNY.

Financial health

How did Alnylam Pharmaceuticals financials performed over time
The total assets is 5% less than the total liabilities
Alnylam Pharmaceuticals's current ratio has decreased by 12% YoY
The company's total liabilities rose by 9% YoY
The equity has contracted by 39% YoY and by 33% from the previous quarter
Alnylam Pharmaceuticals's debt to equity has increased by 29% YoY and by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.